Download MendeleyDiscovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase.
Gentles, R.G., Ding, M., Bender, J.A., Bergstrom, C.P., Grant-Young, K., Hewawasam, P., Hudyma, T., Martin, S., Nickel, A., Regueiro-Ren, A., Tu, Y., Yang, Z., Yeung, K.S., Zheng, X., Chao, S., Sun, J.H., Beno, B.R., Camac, D.M., Chang, C.H., Gao, M., Morin, P.E., Sheriff, S., Tredup, J., Wan, J., Witmer, M.R., Xie, D., Hanumegowda, U., Knipe, J., Mosure, K., Santone, K.S., Parker, D.D., Zhuo, X., Lemm, J., Liu, M., Pelosi, L., Rigat, K., Voss, S., Wang, Y., Wang, Y.K., Colonno, R.J., Gao, M., Roberts, S.B., Gao, Q., Ng, A., Meanwell, N.A., Kadow, J.F.(2014) J Med Chem 57: 1855-1879
- PubMed: 24397558 Search on PubMed
- DOI: https://doi.org/10.1021/jm4016894
- Primary Citation Related Structures:
4NLD - PubMed Abstract:
Described herein are structure-activity relationship studies that resulted in the optimization of the activity of members of a class of cyclopropyl-fused indolobenzazepine HCV NS5B polymerase inhibitors. Subsequent iterations of analogue design and syntheses successfully addressed off-target activities, most notably human pregnane X receptor (hPXR) transactivation, and led to significant improvements in the physicochemical properties of lead compounds. Those analogues exhibiting improved solubility and membrane permeability were shown to have notably enhanced pharmacokinetic profiles. Additionally, a series of alkyl bridged piperazine carboxamides was identified as being of particular interest, and from which the compound BMS-791325 (2) was found to have distinguishing antiviral, safety, and pharmacokinetic properties that resulted in its selection for clinical evaluation.
- Discovery Chemistry, ‡Molecular Discovery Technologies, Molecular Structure & Design, §Molecular Discovery Technologies, Protein Science, ∥Pharmaceutical Candidate Optimization, ⊥Discovery Virology, Disease Sciences and Biologics, #Leads Discovery and Optimization, ▽Materials Science, Drug Product Science and Technology, Bristol-Myers Squibb Research and Development , 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Organizational Affiliation:
